1. Value in Health Regional Issues
Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b 
Phil McEwan, PhD, Thomas Ward, MSc, Samantha Webster, BSc, Yong Yuan, PhD, Anupama Kalsekar, MS, Kristine Broglio, MS, Isao Kamae, PhD, Melanie Quintana, PhD, Scott M. Berry, PhD, Masahiro Kobayashi, MD, Sachie Inoue, PhD, Ann Tang, PhD, Hiromitsu Kumada, MD 
Value in Health Regional Issues 
Volume 3, Pages (May 2014)
DOI: /j.vhri
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Flow diagram of the MONARCH model. CC, compensated cirrhosis; CHC, chronic hepatitis C; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; MONARCH, MOdelling the NAtural histoRy and Cost-effectiveness of Hepatitis; SVR, sustained virological response.
Value in Health Regional Issues 2014 3, DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Estimated cumulative incidence of end-stage liver disease complications (base-case analysis). CC, compensated cirrhosis; DC, decompensated cirrhosis; DCV + ASV, daclatasvir + asunaprevir; HCC, hepatocellular carcinoma; LM, liver-related mortality; TVR + pegIFN-α/RBV, telaprevir + pegylated interferon-alfa + ribavirin.
Value in Health Regional Issues 2014 3, DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions